Azenta, Inc. · Healthcare · Medical Instruments & Supplies
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
At close
$22.96
−$0.48 (−2.03%) Close
Prev closePrevC$23.43
OpenOpen$23.40
Day highHigh$23.53
Day lowLow$22.96
VolumeVol326
Avg volAvgVol1,405,008
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.08B
P/E ratio
-5.93
FY Revenue
$596.33M
EPS
-3.87
Gross Margin
43.85%
Sector
Healthcare
AI report sections
BULLISH
AZTA
Azenta, Inc.
No AI report section text found yet for this symbol.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Azenta, Inc. (AZTA) faces an ongoing securities fraud investigation following disappointing Q2 2026 earnings results on May 5, 2026. The company missed consensus estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance, causing the stock to plummet 25.3% to $18.38 per share. A securities law firm is investigating potential federal securities law violations and urging affected shareholders to contact them.
Company missed Q2 2026 earnings estimates, reported significant goodwill impairment of $149 million, substantially reduced full-year 2026 guidance, and faces securities fraud investigation. Stock price fell 25.3% following the announcement, indicating severe loss of investor confidence.
NegativeGlobeNewswire Inc.• Levi & Korsinsky, Llp
Levi & Korsinsky Announces Investigation of Securities Claims Against Azenta, Inc. (AZTA)
Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026, but disclosed a $149 million goodwill impairment tied to its Multiomics segment in May 2026, alongside a $160.8 million net loss and substantial guidance reduction. The company did not reference the impairment risk during its February reaffirmation, prompting an investigation into potential securities law violations.
Company disclosed a $149 million goodwill impairment and $160.8 million net loss while significantly reducing full-year guidance, just three months after reaffirming positive outlook. The failure to disclose impairment risks during February guidance reaffirmation raises concerns about transparency and potential securities violations, resulting in significant shareholder losses.
Bragar Eagel & Squire, P.C. is Investigating Azenta, Inc. (NASDAQ:AZTA) on Behalf of Azenta Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.
Company disclosed significant operational underperformance with execution gaps, a substantial $149 million goodwill impairment charge, substantial downward revision of full-year guidance (from 3-5% growth to -2% to 1%), and extended timeline for achieving long-range targets. Stock price fell 25% following the announcement, and the company is now subject to a securities investigation.
NegativeGlobeNewswire Inc.• Kirby Mcinerney Llp
AZTA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% on May 6, 2026. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.
Company reported disappointing Q2 results with execution gaps, weak demand environment, $149 million goodwill impairment charge, significant guidance reduction (from 3-5% growth to -2% to +1%), and stock price declined 25% following the announcement. Additionally, securities law violations are being investigated.
NegativeGlobeNewswire Inc.• Schall Law Firm
AZTA Investors Have Opportunity to Join Azenta, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm announced an investigation into Azenta, Inc. for potential securities law violations following the company's May 5, 2026 earnings announcement. Azenta missed analyst estimates on revenue and EPS due to execution shortfalls and weak demand, leading to a 25.3% stock price decline and a reduced full-year 2026 outlook.
The company missed analyst estimates on revenue and EPS, cited execution-related shortfalls and weak demand environment, reduced full-year guidance, and experienced a significant 25.3% stock price decline. Additionally, the company is under investigation for potential securities law violations.
NegativeGlobeNewswire Inc.• Levi & Korsinsky, Llp
AZTA SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Azenta, Inc. for Possible Securities Law Violations
Azenta, Inc. (NASDAQ: AZTA) recorded a $149 million goodwill impairment and slashed FY 2026 guidance on May 5, 2026, just weeks after reaffirming confidence in its growth trajectory on the Q1 earnings call. The impairment was tied to the Multiomics segment. Levi & Korsinsky is investigating whether the company made materially misleading statements to investors regarding risks to the Multiomics segment and factors underlying the goodwill impairment.
Company recorded a $149 million goodwill impairment, posted a $160.8 million net loss, and cut full-year revenue and margin guidance just weeks after reaffirming confidence in its outlook. This represents a significant deterioration in financial performance and investor confidence, with ongoing securities fraud investigation into potentially misleading statements.
NegativeGlobeNewswire Inc.• Kirby Mcinerney Llp
AZTA SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% from $24.61 to $18.38. Law firm Kirby McInerney LLP is investigating potential securities law violations by the company and its senior management.
Company reported disappointing Q2 results with execution gaps, weak demand environment, $149 million goodwill impairment charge, significant reduction in full-year revenue guidance (from 3-5% growth to -2% to +1%), reduced EBITDA margin outlook, and extended timeline for long-range targets. Stock price declined 25% on the announcement, and securities law violations are being investigated.
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
A securities fraud investigation has been announced against Azenta, Inc. after the company missed Q2 2026 earnings estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance. The stock fell 25.3% to $18.38 on May 6, 2026, prompting a law firm to seek investors who suffered losses.
Company missed consensus earnings estimates, reported significant goodwill impairment of $149 million, substantially reduced 2026 revenue guidance from 3-5% growth to -2% to +1%, reduced EBITDA margin outlook, and extended long-range plan targets by one year. Stock price declined 25.3% following the announcement, and a securities fraud investigation has been initiated.
AZENTA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Azenta, Inc. on Behalf of Azenta Stockholders and Encourages Investors to Contact the Firm
Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $24.61 to $18.38 per share.
Company missed Q2 expectations, recorded a $149 million goodwill impairment charge, significantly lowered full-year organic revenue guidance from 3-5% growth to -2% to 1%, reduced EBITDA margin outlook, and extended long-range plan targets by one year. Stock price fell 25% following the announcement, and the company is now subject to a securities investigation.
Azenta Inc (NASDAQ:AZTA) stock fell 13.65% in after-hours trading on Thursday following the filing of a Form 3 with the SEC. William E. Martin III, President of Multiomics at Azenta, submitted an initial statement of beneficial ownership indicating no securities are beneficially owned. The stock closed regular trading at $24.32 (up 3.68%) before declining to $21.00 after-hours.
Stock experienced a significant 13.65% decline in after-hours trading following an SEC Form 3 filing by a company executive. The stock is positioned near the lower end of its 52-week range, and medium- to long-term trends remain negative despite a positive short-term trend.
PositiveGlobeNewswire Inc.• Astute Analytica
Bio-Preservation Market to Reach US$ 44.45 Billion by 2035 | Cold Chain Expansion and Cell & Gene Therapy Commercialization Drive Growth Says Astute Analytica
The global bio-preservation market is projected to grow from USD 4.52 billion in 2025 to USD 44.45 billion by 2035 at a CAGR of 25.68%, driven by cell and gene therapy commercialization, cold chain expansion, and iPSC applications. North America commands 46% market share, with media consumables achieving 32% CAGR. Record FDA approvals (8 in 2024) and 23 anticipated filings in 2025 are accelerating commercial cold chain requirements.
AZTABLFSTMODHLGYbio-preservationcell and gene therapycold chain logisticsiPSC
Sentiment note
Company reached milestone of 300+ automated storage systems globally managing over 1 billion samples, demonstrating strong market position and infrastructure expansion in growing biobanking sector.
NeutralGlobeNewswire Inc.• Marketsandmarkets
Global Biopreservation Market Set to Surpass USD 7.1 Billion by 2029 | MarketsandMarkets™
The biopreservation market is experiencing significant growth driven by healthcare expenditure, research investment, and regenerative medicine, with North America leading and Asia Pacific showing fastest potential expansion. Key challenges include storage logistics and sample transportation standards.
Recognized as a market leader without detailed performance indicators
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
